EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:6 - 60
Updated:12/22/2018
Start Date:October 2, 2018
End Date:October 2, 2022
Contact:Steve B Min, M.D.
Email:steve.b.min.mil@mail.mil
Phone:301-295-4959

Use our guide to learn which trials are right for you!

Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis

The purpose of this study is to evaluate the efficacy of combination therapy with omeprazole
and swallowed fluticasone vs fluticasone therapy and placebo in the treatment of Eosinophilic
Esophagitis (EoE) in children and adults. This study will be a double-blinded, randomized
controlled trial. The primary outcome measured will be histologic assessment of esophageal
tissue biopsies measuring number of eosinophils per high power field (eos/hpf). Secondary
outcomes will be endoscopic findings and symptomatic changes following therapy using
validated endoscopic scoring measures and participant surveys, respectively.

Subjects that meet study inclusion criteria will be recruited from the Adult and Pediatric
Gastroenterology clinics at Walter Reed National Military Medical Center through routine
clinic visits, will meet with an investigator, and complete informed consent/assent. The
participants will then complete a validated clinical symptom reporting tool - the
Eosinophilic Esophagitis symptom activity index (EEsAI) for age 18 and above, or the
Pediatric Quality of Life Inventory (PedsQL) for age 6-17yrs - and have their initial
Esophagogastroduodenoscopy (EGD) images evaluated via a validated Endoscopic Reference Score
(EREFS). Esophageal biopsies taken at the patient's initial EGD will be assessed by 2
designated blinded pathologists to record the number of eosinophils per high power field
(HPF), as well as perform tissue immunohistochemical staining for eotaxin-3. Participants
will be block randomized to treatment or control groups and complete 8 weeks of therapy, with
a phone follow up at 4 weeks for medication compliance. At the completion of 8 weeks of
therapy, the participants will have repeat EGD to assess for mucosal healing, which is the
standard of care in the treatment of EoE. At this EGD, the images will be assigned an EREFS
and the biopsies will be evaluated for eosinophils per high powered field and eotaxin-3
staining. The patient will also complete an EEsAI or PedsQL. This procedure will end the 8
week study period.

Inclusion Criteria:

- age 6 to 60 years old

- DEERS (defense enrollment eligibility reporting system) eligible

- diagnosis of eosinophilic esophagitis

Exclusion Criteria:

- Outside of age range

- Co-existing inflammatory gastroenterologic condition such as celiac disease,
eosinophilic esophagitis, or inflammatory bowel disease.

- Concurrent use of oral steroids

- Pregnancy

- Refusal to undergo endoscopy
We found this trial at
1
site
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Phone: 443-904-3353
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials